<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464631</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HCV-001</org_study_id>
    <nct_id>NCT02464631</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis</brief_title>
  <official_title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis&quot; - A Randomized Open- Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized trial, A Minimum of 300 consecutive patients of decompensated
      HCV (Hepatitis C Virus) related cirrhosis, presenting to the Institute of Liver and Biliary
      Sciences hospital will be included and those patients meeting the entry criteria received
      treatment with 400 mg of Sofosbuvir, administered orally once daily, and Ribavirin
      administered orally twice daily, with doses determined according to body weight(600 mg daily
      in patients with a body weight of ≤60 kg,800 mg daily in patients weighing &gt;60 and ≤80 kg,
      and1000 mg daily in patients with a body weight of &gt;80 kg). Based on the treatment duration,
      patients would be randomized in either of the 3 treatment groups -

        -  Group 1 - Sofosbuvir + Ribavirin x 24 weeks

        -  Group 2 - Sofosbuvir + Ribavirin x 36 weeks

        -  Group 3 - Sofosbuvir + Ribavirin x 48 weeks
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir
    and Ledipasvir which have proven better efficacy in the HCV cure
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary efficacy end point is SVR 24 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint is any AE (Adverse Event) leading to permanent discontinuation of study drugs.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 6 months post therapy in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the liver function as determined by CTP (Child-Turcotte-Pugh score), MELD (Model for End Stage liver Disease)more than 2 points at 6 months and 1 year.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new cases of Hepatocellular Carcinoma at end of therapy and at 6 months post therapy in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HVPG &gt;20% to baseline after 1 year in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 4 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>HCV Related Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 1</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 2</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 3</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female ≥ 18 yrs

          -  Baseline HCV RNA &gt; 1000 IU/ml

          -  Cirrhosis with current or prior decompensation

          -  HCV (Hepatitis C Infection) Genotype 3

          -  Treatment naïve or treatment experienced

        Exclusion Criteria:

          -  HIV or HBV (Hepatitis B Virus) co-infection

          -  Recent Variceal bleed

          -  Pregnancy

          -  Haemolytic anaemia

          -  Platelet counts &lt;20,000/ml

          -  Advanced HCC (Hepatocellular Carcinoma)

          -  Renal dysfunction, GFR (glomerular filtration rate) &lt; 30 ml/min

          -  Haemoglobin &lt; 10 g/dl

          -  MELD (Model for End Stage Liver Disease) &gt;25, CTP (Child-Turcotte-Pugh score) &gt;12

          -  Post organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ankur Jindal, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

